Non-Small Cell Lung Cancer – An Introduction

[music] Non-small cell cancer is the most common kind
of lung cancer. It will affect approximately 170,000 Americans
this year. Essentially it is a cancer that forms in the
lung, and we call it non-small cell, because that’s what it looks like under the microscope. The reason that we lump all of non-small cell
lung cancer together is the staging and prognosis is very similar and treatment is very similar. So people with early stage disease undergo
surgery or radiation, patients with more distant disease may often have systemic chemotherapy,
or immunotherapy, targeted therapy as their initial treatment. We subdivide non-small cell lung cancer into
different types based on what the cells look like and where the cell of origin is. So, commonly we’ll talk about adenocarcinoma. Those come from the end of the respiratory
tree from the alveoli that make our, that is where our oxygen and blood is interchanged. Squamous cell cancers are second most common
and those come from the linings of the respiratory tree. And then a less common variant is large cell
and neuroendocrine non-small cell. Those are our three major histologic types. The first thing that you need to know that
whatever stage it is, it’s very treatable. You think about what stage do I have, because
that allocates the appropriate treatment. If I am a candidate for chemotherapy, or immunotherapy,
or targeted therapy, you want to understand which would be the best in your particular
situation, and that often comes from pathologic testing. And staging often includes some radiologic
tests, like CT scans, MRI’s of the brain, or PET scans and that gives us the anatomy
and sort of the extent of the disease. The next part of staging, of finding out more
about your particular kind of lung cancer, is to understand either the histologic diagnosis,
so that’s adenocarcinoma, squamous cell, or large cell neuroendocrine tumor, because
that has relevance on additional biomarker testing and has relevance in what kind of
chemotherapy would be given if it’s appropriate for your stage of disease. The next piece, and the piece that’s so
important to us now, is understanding if there is a genetic code that we can target in some
cancers. So, particularly if there is a non-squamous
tumor we recommend genetic testing to see if there are particular proteins or mutations,
genetic mutations that we can target for more effective therapies. The treatment of non-small cell lung cancer
depends primarily on the stage of disease. So if you have early stage, which we consider
Stage I and II, often local therapy is the best initial treatment. So Stage I means that the tumor is confined
to your lung. Stage II means that lymph nodes within the
lung are involved. For those patients, an early referral to surgery
is usually the best initial step. Stage III disease is also often termed locally
advanced, and that means that the cancer has generally spread to the lymph nodes in the
center of your chest, sometime we call these mediastinal lymph nodes. These lymph nodes are close to the windpipe,
and other essential blood vessels, and the heart, and often make resection with clear
margin—so space around the tumor—really impossible. And so what we tend to do is to do some sort
of systemic therapy, that’s usually chemotherapy. And then we give local treatment, and that’s
either radiation or surgery. This is a complex treatment plan, and it’s
usually done with a team of doctors, like radiation oncologist, surgeons, and pulmonologists. Patients who have Stage IV disease have cancer
that spread to another organ, commonly that’s the bone, or the brain, liver, or adrenal
glands, or it’s a tumor that has gone to the lining of the lung called the pleura,
or to multiple sites in both lungs. Those patients are generally treated with
systemic therapy. Most patients still get chemotherapy, the
chemotherapy is much more tolerable than it ever has been. And it might be that treatment is once every
three weeks, or every other week for some individuals. Targeted therapy is often a pill that’s
given as a tablet every day at home and that is therapy that targets a particular protein
that’s malfunctioning and causing the cancer to grow. Immunotherapy has gained significant steam
in the past year or two, and that’s because we’ve realized that in some people that
have a high biomarker called PD-L1, that initial immunotherapy may be the first most appropriate
treatment. Immunotherapy is generally an infusion given
every once, once every 3 weeks or sometimes every 2 weeks, and that means it’s given
by vein and it’s an antibody, a protein that blocks, this protein that’s upregulated,
and by blocking it enables the immune system to function again to treat the cancer. In non-small cell lung cancer, we’ve made
significant strides, really in 2 categories, one is understanding how we can use immunotherapy
to treat patients and to improve outcome. So some studies have shown that combining
immunotherapy with chemotherapy looks very exciting and improves the time until the cancer
grows again. Other studies have shown that up front treatment
of patients with immunotherapy by itself may improve outcome. We’re learning now that there may be a priming
effect either with chemotherapy or with radiation to make immunotherapy more effective. So there are multiple trials that are ongoing
understanding the best sequence of events. This is new territory for us, so the learning
curve is rapid. When people ask me about survival expectations
at 2 and 3 years, this is something that we’re just learning about, because now we’re finally
seeing patients who are living beyond what any of our expectations were before. The other big piece of cancer therapy and
one that should not be overshadowed by the huge leaps we’ve made in immunotherapy,
is really that we’ve, have a good understanding of many of the mutations that drive cancer,
and this genomic profiling that’s usually done on tumor cells, sometimes is done in
the blood, helps direct us to particular mutations that we can target. We know that targeting therapy, targeting
cancer with particular therapy is, is very effective. Often it means that we see fewer side effects
because we’re just treating the cancer cells, and we know that we can see dramatic results
with shrinkage and some, in some populations in 70 or 80 percent of patients who have these
particular mutations. The challenge is that these targeted therapies
often work for some time. Some studies are showing several years of
duration, but that often cancer gets smart and can find a way to outwit even the targeted
therapy, and so now many research efforts are looking at, what do we do in the second,
third, and fourth line setting in the patients who have had these oral therapies that have
been so effective. If you’re diagnosed with non-small cell
cancer, someone you care about is diagnosed with cancer, I’d suggest going to Cancer.Net,
there’s a lot of information there about particular cancers, about strategies for staying
healthy and living with cancer, as well as caregiving. [music]

Leave a Reply

Your email address will not be published. Required fields are marked *